Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 3/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401343 | 1.00 | CYP2D6 (0.50) | CYP2D6KMT2AMEN1MMP2ANPEP | |
| SCHEMBL25544479 | 1.00 | CYP2D6 (0.50) | CYP2D6KMT2AMEN1MMP2ANPEP | |
| SCHEMBL10452486 | 0.90 | CYP2D6 (0.50) | CYP2D6KMT2AMEN1MMP2ANPEP | |
| SCHEMBL10452485 | 0.90 | CYP2D6 (0.50) | CYP2D6KMT2AMEN1MMP2ANPEP | |
| SCHEMBL10452488 | 0.90 | CYP2D6 (0.50) | CYP2D6KMT2AMEN1MMP2ANPEP | |
| SCHEMBL22230736 | 0.88 | CYP2D6 (0.48) | CYP2D6KMT2AMMP2ANPEPALDH1A1 | |
| SCHEMBL4522264 | 0.88 | CYP2D6 (0.48) | CYP2D6KMT2AMMP2ANPEPALDH1A1 | |
| SCHEMBL4522270 | 0.88 | CYP2D6 (0.48) | CYP2D6KMT2AMMP2ANPEPALDH1A1 | |
| SCHEMBL4522267 | 0.88 | CYP2D6 (0.48) | CYP2D6KMT2AMMP2ANPEPALDH1A1 | |
| SCHEMBL27214135 | 0.87 | CYP2D6 (0.56) | CYP2D6KMT2AMEN1MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3980412-B1 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12319671-B2 | 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240366518-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | LIFE EDIT THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118324715-A | Compounds, compositions, and methods of use thereof | 艾勒维生技公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240173267-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | ONCORUS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2024-05-02 | — | — | US | disclosed |
| CN-117750962-A | Compounds, compositions, and methods of use thereof | 艾勒维生技公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| EP-3833438-B1 | SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4291201-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Oncorus, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-7820662-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-7521448-B2 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1740591-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2005097800-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | KIT, CHUK, TNNI3K | CYP2D6 2814/4885KMT2A 518/4885MEN1 979/4885 |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | CYP2D6 467/4885KMT2A 3065/4885MEN1 1368/4885 |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | CYP2D6 467/4885KMT2A 3065/4885MEN1 1368/4885 |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CYP2D6 958/4885KMT2A 1568/4885MEN1 1411/4885 |
| US-20240173267-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | POLRMT, POLN, NSUN2 | CYP2D6 3210/4885KMT2A 2317/4885MEN1 2485/4885 |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | CYP2D6 3015/4885KMT2A 2286/4885MEN1 169/4885 |
| US-20240366518-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | POLRMT, POLN, NSUN2 | CYP2D6 3210/4885KMT2A 2317/4885MEN1 2485/4885 |
| US-12319671-B2 | 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, BRSK2 | CYP2D6 2873/4885KMT2A 2095/4885MEN1 4342/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | CYP2D6 467/4885KMT2A 3065/4885MEN1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.